Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26346638 | 0.90 | GLP1R (0.40) | GLP1RTSHR | |
| SCHEMBL26346642 | 0.88 | MEN1 (0.35) | CRBNMEN1KMT2A | |
| SCHEMBL26346649 | 0.85 | MEN1 (0.31) | CRBNMEN1KMT2A | |
| SCHEMBL17282361 | 0.81 | CRBN (0.41) | CRBNMEN1KMT2ATSHRCA12 | |
| SCHEMBL18886281 | 0.81 | CRBN (0.41) | CRBNMEN1KMT2ATSHRCA12 | |
| SCHEMBL30980666 | 0.81 | CRBN (0.37) | GLP1RCRBNMEN1KMT2AALDH1A1 | |
| SCHEMBL25431962 | 0.80 | GLP1R (0.45) | GLP1RCRBNMEN1KMT2A | |
| SCHEMBL25431966 | 0.80 | GLP1R (0.45) | GLP1RCRBNMEN1KMT2A | |
| SCHEMBL13695963 | 0.79 | CASP2 (0.41) | CRBNMEN1KMT2ACA12CA1 | |
| SCHEMBL30377114 | 0.79 | CASP2 (0.41) | CRBNMEN1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303649-A1 | MODIFIED IL-2 POLYPEPTIDES FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | IL2, IL2RA, ICOS | GLP1R 157/4885CRBN 1005/4885MEN1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.